This trial evaluates how well CPX-351 and enasidenib work in treating patients with acute
myeloid leukemia characterized by IHD2 mutation. Drugs used in chemotherapy, such as CPX-351,
work in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the
growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351
and enasidenib may work better in treating patients with acute myeloid leukemia, compared to
giving only one of these therapies alone.
Phase:
Phase 2
Details
Lead Sponsor:
Jonsson Comprehensive Cancer Center
Collaborators:
Jazz Pharmaceuticals National Cancer Institute (NCI)